1. Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept
- Author
-
Juan Ignacio Muñoz, Andrea Estébanez, Carlos Monteagudo, Alicia Monrabal, M. D. Ramon, Luis Carlos Sáez-Martín, and Esmeralda Silva
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,biology ,business.industry ,Dermatology ,medicine.disease ,Toxic epidermal necrolysis ,Infliximab ,Etanercept ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,biology.protein ,medicine ,Tumor necrosis factor alpha ,Levetiracetam ,Antibody ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.
- Published
- 2020
- Full Text
- View/download PDF